EQS-News: Apogenix AG: Apogenix' new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

EQS-News: Apogenix AG / Key word(s): Scientific publication Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model 01.06.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Apogenix’ new CD40 agonist...

Related Keywords

United Kingdom ,Germany ,Heidelberg ,Baden Wüberg ,Manchester ,Tim Illidge ,Brigitte Keller ,Judith Teumer ,Katja Arnold ,Thomas Hoeger ,Mc Services ,European Medicines Agency ,Distribution Services ,University Of Manchester ,Professor Tim Illidge ,Tumor Necrosis Factor Receptor Superfamily ,Superfamily Agonists ,Corporate News ,Regulatory Announcements ,Eqs News ,Apogenix ,G ,Key ,Cientific ,Cd40 ,Era Cd40l ,Et Cest ,The ,